

NOTICE OF REGULAR BOARD MEETING AND RULE HEARING

The New Mexico Board of Pharmacy will convene for the purpose of conducting a rule hearing and regular board meeting on April 22, 2021 at 9:00 a.m. and continue until finished. If the meeting agenda items are not finished by 5:00 p.m., the Board will convene on April 23, 2021 at 9:00 a.m. and continue until finished. Pursuant to the June 12, 2020 Public Health Order restricting Mass Gatherings due to COVID-19, the rule hearing and meeting will be held virtually via Cisco WebEx.

Location: Virtual meeting

April 22, 2021

Meeting link: <https://nmrld.webex.com/nmrld/onstage/g.php?MTID=e9f6018e4fc709c9d2d32ca7685a2f44f>

Meeting number: 146 081 4992

Password: kiPsXuC7m74

Join by phone +1-415-655-0002 United States Toll

Access code: 146 081 4992

April 23, 2021

Meeting link: <https://nmrld.webex.com/nmrld/onstage/g.php?MTID=e2763712013e443347a0f7dd32cc2d58c>

Meeting number: 146 042 8437

Password: tGEDsDdz422

Join by phone +1-415-655-0002 United States Toll

Access code: 146 042 8437

The agenda is posted 72 hours prior to the scheduled meeting. You may view and download a copy of the agenda through the board's website: www.rld.state.nm.us/boards/pharmacy.aspx. All proposed language regarding rule hearings is linked to the Agenda, the Notice to the Public on our website, and the New Mexico Sunshine Portal.

Individuals petitioning the board regarding requests/waivers and/or interested persons wishing to comment on proposed language regarding rule hearings must submit documentation for presentation; via fax (505) 222-9835, mail or email to the Board Administrator, Gabriella Romero, gabriella.romero@state.nm.us at least one week in advance of the scheduled meeting, as public comment is allowed during the rule hearing. On the morning of the hearing beginning at 8:00 a.m. and ending when the rule hearing adjourns, a board of pharmacy representative will be stationed at the board office, located at 5500 San Antonio Drive NE, Albuquerque, NM 87109, to receive written comments regarding the rule hearings and also to convey them to the Board. Public attendance will be limited to remote participation. Oral participation by members of the public will be limited to those comments and discussion through audiovisual means.

The board may go into Executive Session to discuss items pursuant to Section 10-15-1H(1), Section 10-15-1H(2), Section 10-15-1H(3) or Section 10-15-1H(7) of the Open Meeting Act. Agenda items may be executed at any time during the meeting to accommodate hearings.

If you are an individual with a disability who is in need of a reader, amplifier, qualified sign language interpreter, or any other form of auxiliary aid or service to attend or participate in the hearing or meeting, please contact Gabriella Romero 505-222-9835 at least one week prior to the meeting or as soon as possible. Public documents, including the agenda and minutes, can be provided in various accessible formats. Please contact Gabriella Romero, at 505-222-9835 or e-mail gabriella.romero@state.nm.us if a summary or other type of accessible format is needed.

The Board will address:

All Board Matters:

Rule Hearing: April 22, 2021 9:10 a.m.

16.19.26 NMAC - PHARMACIST PRESCRIPTIVE AUTHORITY: Sections 1 and 3 – administrative updates. Section 7 – update definition of hormonal contraception drug therapy to clearly encompass formulary products delineated in the written contraception protocol approved by the board, including emergency contraception. The formulary, which was approved by the medical board and board of nursing, is unchanged. Section 9 – remove requirement to notify the department of health immunization program and patient’s designated physician of vaccine administration, as the pharmacist is required to update the department of health immunization program’s electronic database (NMSIIS) for any vaccine administered. Sections 10, 11, 12, 13 and 14 - Deletion of Section 10, emergency contraception drug therapy. Emergency contraception is included in the approved protocol formulary for the hormonal contraception drug therapy section, which was promulgated subsequent to the emergency contraception section. The hormonal contraception drug therapy definition is clarified accordingly, as above. Subsequent sections 10-13 (previously 11-14) are renumbered. Renumbered section 11, TB testing, education and training is updated to reference training providers. New section 14, prescribing dangerous drugs in conjunction with point-of-care testing – addresses pharmacist prescribing of protocol formulary dangerous drugs, specifies required education and training, records and notification. The final protocol is subject to board approval following medical board and board of nursing approval.

STATUTORY AUTHORITY: Paragraphs (1), (7) and (19) of Subsection (A) of Section 61-11-6 NMSA 1978. Sections 61-11B-1 to 61-11B-3 NMSA 1978.

Disciplinary Hearing(s): At the time of publication in the NM Register, no disciplinary hearings are scheduled. Final hearing date and time for each case, if any, will be included in the agenda posted to the board’s website at least 72 hours before the meeting.

Executive Director’s Report:

Published in NM Register March 9, 2021

Published in Albuquerque Journal March 9, 2021